Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction

Core Insights - Nutriband is developing Aversa™ Fentanyl, an abuse-deterrent transdermal system that combines proprietary technology with an FDA-approved fentanyl patch [2][5] - The designation of illicit fentanyl as a weapon of mass destruction highlights the dangers of illegal fentanyl while distinguishing it from FDA-approved prescription therapies [4][3] - Aversa™ Fentanyl has the potential to achieve peak annual US sales between $80 million to $200 million, addressing a significant unmet medical need for pain management [6] Company Overview - Nutriband Inc. focuses on developing a portfolio of transdermal pharmaceutical products, with Aversa™ as its lead product [10] - The company is collaborating with Kindeva to enhance the safety profile of transdermal drugs susceptible to abuse [5][10] - Nutriband's AVERSA™ technology is protected by a broad international intellectual property portfolio, with patents issued in 46 countries [7][9] Industry Context - Prescription transdermal fentanyl is critical for managing pain in opioid-tolerant patients, but abuse and accidental exposures remain significant issues [4] - The opioid epidemic continues to drive the need for safer alternatives in pain management, emphasizing the importance of abuse-deterrent technologies [4][6] - The regulatory landscape is evolving, with the US government taking measures to combat illegal fentanyl while ensuring access to necessary medical treatments [3][4]